接种疫苗的慢性肺病患者Delta与Omicron变异株感染结局:全国队列研究
本研究在新加坡高度接种疫苗及加强针的成年慢性肺病患者中,对比Delta和Omicron变异株感染结局与匹配人群对照。结果显示慢性肺病患者感染、住院及重症COVID-19风险均升高,Omicron期重症风险更高;既往一年严重急性加重与不良结局强相关,加强接种可减弱风险。
要点
- 慢性肺病患者在Delta和Omicron期感染、住院及重症COVID-19风险均高于匹配对照。
- Omicron期哮喘和COPD患者重症COVID-19风险仍显著升高。
- 既往一年因严重急性加重住院者不良结局风险极高,加强接种可减弱风险。
核心结论
- 在Delta和Omicron流行期间,慢性肺病患者较匹配人群对照有更高的COVID-19相关住院和重症风险。
- 加强接种可减弱重症COVID-19结局风险。
研究设计与样本
- 全国性基于人群的队列研究,纳入68,782例慢性肺病成人患者和534,364例匹配人群对照。
- 慢性肺病包括哮喘、COPD、支气管扩张和肺纤维化;采用日历时间尺度Cox回归比较感染、住院和重症风险,调整社会人口学因素和合并症。
主要发现
- Delta期慢性肺病患者较对照感染aHR 1.22(95%CI 1.17-1.28)、住院aHR 1.76(95%CI 1.61-1.92)、重症aHR 1.75(95%CI 1.50-2.05)。
- Omicron期慢性肺病患者较对照感染aHR 1.15(95%CI 1.14-1.17)、住院aHR 1.82(95%CI 1.74-1.91)、重症aHR 2.39(95%CI 2.18-2.63)。
- Omicron期哮喘患者重症aHR 1.31(95%CI 1.10-1.55),COPD患者重症aHR 1.36(95%CI 1.12-1.66)。
- 既往一年严重急性加重需住院者,Delta期重症aHR 9.84(95%CI 6.33-15.28),Omicron期重症aHR 19.22(95%CI 15.35-24.06)。
- 加强组风险减弱,四剂组较三剂组住院和重症COVID-19的HR数值更低。
关键数值与推荐
- 截至Omicron波结束,92.7%的慢性肺病患者已接种加强针。
临床怎么用
- 对慢性肺病患者应重视COVID-19疫苗接种及加强接种,以降低住院和重症风险。
- 既往一年因严重急性加重住院的慢性肺病患者属高危人群,需强化防护和随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Individuals with chronic lung disease (CLD) are more susceptible to respiratory viral infections; however, significant heterogeneity exists in the literature on CLD and COVID-19 outcomes. Data are lacking on outcomes with newer variants (eg, Omicron) and in vaccinated and boosted populations. RESEARCH QUESTION: What are the outcomes of SARS-CoV-2 infection in individuals with CLD during Delta and Omicron transmission in a highly vaccinated and boosted population-based cohort? STUDY DESIGN AND METHODS: Outcomes of Delta and Omicron SARS-CoV-2 infection in a highly vaccinated and boosted cohort of adult Singaporeans with CLD (including asthma, COPD, bronchiectasis, and pulmonary fibrosis) were contrasted against matched population control participants. Calendar time-scale Cox regressions were used to compare risk of infection, COVID-19-related hospitalizations, and severe COVID-19 disease, adjusting for sociodemographic factors and comorbidities. RESULTS: Overall, 68,782 individual patients with CLD and 534,364 matched population control participants were included. By the end of the Omicron wave, 92.7% of patients with CLD were boosted. Compared with control participants, patients with CLD showed higher risk of SARS-CoV-2 infection, COVID-19-related hospitalization, and severe COVID-19 during both the Delta wave (infection: adjusted hazards ratio [aHR], 1.22 [95% CI, 1.17-1.28]; hospitalization: aHR, 1.76 [95% CI, 1.61-1.92]; severe COVID-19: aHR, 1.75 [95% CI, 1.50-2.05]) and Omicron wave (infection: aHR, 1.15 [95% CI, 1.14-1.17]; hospitalization: aHR, 1.82 [95% CI, 1.74-1.91]; severe COVID-19: aHR, 2.39 [95% CI, 2.18-2.63]). During Omicron, significantly higher risk of infection, hospitalization, and severe COVID-19 was observed among patients with asthma (severe COVID-19: aHR, 1.31 [95% CI, 1.10-1.55]) and COPD (severe COVID-19: aHR, 1.36 [95% CI, 1.12-1.66]) compared with control participants. Severe exacerbation (requiring hospitalization) in the preceding year was associated with higher risk of poorer outcomes (Delta, severe COVID-19: aHR, 9.84 [95% CI, 6.33-15.28]; Omicron, severe COVID-19: aHR, 19.22 [95% CI, 15.35-24.06]). Risk was attenuated in the boosted group, with numerically lower HRs against hospitalization and severe COVID-19 in the four-dose group compared with the three-dose group. INTERPRETATION: Increased risk of COVID-19-related hospitalization and severe COVID-19 was observed among patients with CLD compared with matched population control participants during Delta and Omicron predominance. Boosting attenuated serious COVID-19 outcomes.
引用
- Wee, Tan, Chiew, et al. A Nationwide Cohort Study of Delta and Omicron SARS-CoV-2 Outcomes in Vaccinated Individuals With Chronic Lung Disease. Chest. 2024. PMID: 38871281. doi:10.1016/j.chest.2024.05.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。